^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
beta alethine (Ax-101)
i
Other names: Ax-101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AxImmune
Drug class:
IL-2 stimulant, IL-10 inhibitor
Related drugs:
3years
[VIRTUAL] Ax-101, an immunostimulatory small molecule, markedly enhances the antitumor activity of PD1 immune checkpoint blockade in multiple preclinical solid tumor models (AACR 2021)
Consistent with Ax-101 activity depending on a functional immune system, delayed type hypersensitivity (DTH) testing showed all responders to be DTH+ (5 tumor reduction, 4 SD); 5 anergic (DTH-) patients had SD at best (2 SD, 3 worse). Current Ax-101 clinical development will leverage its beneficial immunostimulatory properties to augment the efficacy of anti-PD1 inhibitors such as pembrolizumab, nivolumab and cemiplimab.
Preclinical • Checkpoint inhibition
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Libtayo (cemiplimab-rwlc) • beta alethine (Ax-101)
Share via
